Imatinib reduces bone marrow fibrosis and overwhelms the adverse prognostic impact of reticulin formation in patients with chronic myeloid leukaemia

Date
2016
Author
Buyru, Ayse Nur
Simsek, Eda Tanrikulu
Ekizoglu, Seda
Gulturk, Emine
Ferhanoglu, Burhan
Tuzuner, Nukhet
Demiroz, Ahu Senem
Aydin, Seniz Ongoren
Aydin, Yildiz
Soysal, Teoman
Ozbek, Ugur
Baslar, Zafer
Salihoglu, Ayse
Elverdi, Tugrul
Ar, Muhlis Cem
Eskazan, Ahmet Emre
Cengiz, Mahir
Metadata
Show full item record
Abstract
Aims Before the era of tyrosine kinase inhibitors (TKIs), the presence of bone marrow fibrosis (MF) in patients with chronic myeloid leukaemia (CML) has been established as a poor prognostic factor. The aim of the present study was to evaluate the effects of imatinib treatment on MF and the prognostic significance of MF at this new era of CML therapy.
URI
http://hdl.handle.net/20.500.12627/91282
https://doi.org/10.1136/jclinpath-2015-203320
Collections